Binimetinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Binimetinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
153
Registered trials
172
Result records
8
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Binimetinib can convert its Small molecule drug profile and MEK1 x MEK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Binimetinib (query alias: binimetinib) |
|---|---|
| Modality / target | Small molecule drug; MEK1 x MEK2; MEK1 inhibitors, MEK2 inhibitors |
| Highest global status | Approved |
| Originator | Array BioPharma, Inc. |
| Active developers | OnKure, Inc., Pfizer Inc., Pierre Fabre Medicament Information |
The MCP disease footprint includes Non-Small Cell Lung Cancer, BRAF mutated anaplastic thyroid cancer, Thyroid Cancer with BRAF mutation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT1031260160 | Not Applicable | 募集中 | 130 | 治療状況 ‧ENC+BIN併⽤療法投与開始時の患者情報（年齢、性別、組織型、遠隔転移の有無、転移部位等） ‧ ENC+BIN併⽤療法の治療状況（投与期間、継続/減量/休薬/中⽌率、投与量、休薬/中⽌理由 等） 有効性 ・RECIST ver1.1に準拠した主治医評価による全奏効率 安全性 ・ENC+BIN併⽤療法投与開始から最終投与後28日以内の有害事象の発現割合 |
| NCT07022457 | Not Applicable | Active, not recruiting | 50 | Describe the change from baseline over 24 months of FACT-Melanoma (FACT-M) scores of patients initiated on encorafenib plus binimetinib |
| CTR20261458 | Not Applicable | 进行中 （尚未招募） | 48 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A multicenter phase II trial of encorafenib, binimetinib, and cetuximab for early relapsed stage II/III BRAF<sup>V600E</sup>-mutated colorectal cancer: TRESBIEN trial (OGSG 2101).
Phase 2; n=25; evaluation: Positive. Reported fields: ORR = 62.5 % ( 40.6 - 81.2)
A phase II trial of binimetinib in combination with encorafenib in patients with pancreatic malignancies and a somatic BRAF<sup>V600E</sup> mutation.
Phase 2; n=6; evaluation: Positive. Reported fields: AE(Grade ≥3) = 50.0 %
Overall survival benefit of doublet versus triplet BRAF inhibitor–based therapy: Insights from the BEETS study (JACCRO CC-18).
Not Applicable; n=162; evaluation: Positive. Reported fields: mOS(RAD51C High) = 12.9 month ; mOS(RAD51C High) = 28.2 month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Binimetinib addresses Non-Small Cell Lung Cancer, BRAF mutated anaplastic thyroid cancer, Thyroid Cancer with BRAF mutation. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-11-26 | 皮尔法伯与国药控股达成战略合作 共拓中国肿瘤治疗新格局 | Approved | Financial terms not disclosed |
| 2022-09-13 | Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer | Approved | Financial terms not disclosed |
| 2020-09-21 | OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
